Ikena Oncology Valuation
| IKNA Stock | USD 1.50 0.01 0.66% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Ikena Oncology retains a regular Real Value of $1.86 per share. The prevalent price of the firm is $1.5. Our model calculates the value of Ikena Oncology from evaluating the firm fundamentals such as Shares Outstanding of 48.26 M, return on equity of -0.37, and Return On Asset of -0.22 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Ikena Oncology's valuation include:
Price Book 0.5393 | Enterprise Value | Enterprise Value Ebitda (0.54) | Price Sales 110.5762 | Enterprise Value Revenue 0.9337 |
Undervalued
Today
Please note that Ikena Oncology's price fluctuation is unstable at this time. Calculation of the real value of Ikena Oncology is based on 3 months time horizon. Increasing Ikena Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Ikena Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ikena Stock. However, Ikena Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.5 | Real 1.86 | Target 3.0 | Hype 1.5 |
The real value of Ikena Stock, also known as its intrinsic value, is the underlying worth of Ikena Oncology Company, which is reflected in its stock price. It is based on Ikena Oncology's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Ikena Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Ikena Oncology helps investors to forecast how Ikena stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ikena Oncology more accurately as focusing exclusively on Ikena Oncology's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Ikena Oncology's intrinsic value based on its ongoing forecasts of Ikena Oncology's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Ikena Oncology's closest peers. If more than one evaluation category is relevant for Ikena Oncology we suggest using both methods to arrive at a better estimate.
Ikena Oncology Cash |
|
Ikena Valuation Trend
Comparing Ikena Oncology's enterprise value against its market capitalization is a good way to estimate the value of Ikena Oncology uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Ikena Oncology Total Value Analysis
Ikena Oncology is currently estimated to have valuation of (57.25 M) with market capitalization of 72.87 M, debt of 10.74 M, and cash on hands of 192.81 M. The negative valuation of Ikena Oncology may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Ikena Oncology fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(57.25 M) | 72.87 M | 10.74 M | 192.81 M |
Ikena Oncology Investor Information
About 69.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.54. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ikena Oncology recorded a loss per share of 1.22. The entity had not issued any dividends in recent years. Based on the key measurements obtained from Ikena Oncology's financial statements, Ikena Oncology is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.Ikena Oncology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Ikena Oncology has an asset utilization ratio of 4.77 percent. This suggests that the Company is making $0.0477 for each dollar of assets. An increasing asset utilization means that Ikena Oncology is more efficient with each dollar of assets it utilizes for everyday operations.Ikena Oncology Ownership Allocation
Ikena Oncology has a total of 48.26 Million outstanding shares. Over half of Ikena Oncology's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Ikena Oncology Profitability Analysis
The company reported the previous year's revenue of 9.16 M. Net Loss for the year was (68.17 M) with loss before overhead, payroll, taxes, and interest of (39.91 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Ikena Oncology's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Ikena Oncology and how it compares across the competition.
About Ikena Oncology Valuation
The stock valuation mechanism determines Ikena Oncology's current worth on a weekly basis. Our valuation model uses a comparative analysis of Ikena Oncology. We calculate exposure to Ikena Oncology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Ikena Oncology's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 9.4 M | 9.8 M | |
| Pretax Profit Margin | (6.71) | (7.05) | |
| Operating Profit Margin | (7.41) | (7.78) | |
| Net Loss | (6.70) | (7.03) | |
| Gross Profit Margin | 0.80 | 0.84 |
Ikena Oncology Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 41.7 M |
Ikena Oncology Current Valuation Indicators
Valuation refers to the process of determining the present value of Ikena Oncology and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Ikena we look at many different elements of the entity such as Ikena's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Ikena Oncology, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Ikena Oncology's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Ikena Oncology's worth.Complementary Tools for Ikena Stock analysis
When running Ikena Oncology's price analysis, check to measure Ikena Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ikena Oncology is operating at the current time. Most of Ikena Oncology's value examination focuses on studying past and present price action to predict the probability of Ikena Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ikena Oncology's price. Additionally, you may evaluate how the addition of Ikena Oncology to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |